|
|
|
Market Research Report
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010
| Published by |
iData Research Inc. |
| Published |
December, 2009 |
Product code |
99203 |
| Content info |
304 Pages |
| Price |
|
|
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010 published by iData Research Inc. in December, 2009. This report consists of 304 Pages and the price starts from US $ 6995.
Abstract
Summary
There are currently over 23.6 million people in the U.S., or almost 8% of the
population who have diabetes. The diabetes market is expected to show
substantial growth due to the obesity epidemic in the U.S., now becoming known
as diabesity. The U.S. Market for Diabetes Monitoring, Treatment and Drug
Delivery includes blood glucose diagnosis and monitoring including traditional
blood glucose monitors, continuous glucose monitoring systems (CGM), blood
glucose test strips, lancets and lancing devices. This market also includes
the markets for insulin and insulin delivery devices including syringes, pens,
pumps and jet injectors as well as Oral anti-diabetic drugs.
iData Research's 2009 report on the U.S. Diabetes Monitoring, Treatment and Drug Delivery offers comprehensive coverage on:
- Blood Glucose Meters
- Continuous Blood Glucose Monitoring Systems
- Blood Glucose test Strips
- Lancets and Lancing Devices
- Insulin
- Insulin Syringes
- Insulin Pens
- Insulin Pumps
- Oral Anti-Diabetic Drugs
- Injectable Anti-Diabetic Drugs
U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery
Leading Competitors on the Patient Monitoring Equipment Market: (A short list, alphabetical)
- Abbott
- Amylin
- Allison
- Bayer
- Becton Dickinson
- Bristol-Myers Squibb
- Covidien
- Eli Lily
- Many More..
Table of Contents
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF CHARTS
EXECUTIVE SUMMARY
- 1.1 U.S. MARKET FOR DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY
- 1.2 TREND ANALYSIS BY SEGMENT
- 1.3 BLOOD GLUCOSE MONITORING MARKET
- 1.4 DIABETIC POPULATION
- 1.5 INSULIN
- 1.6 INSULIN SYRINGES
- 1.7 INSULIN PENS
- 1.8 INSULIN PUMPS
- 1.9 ORAL ANTIDIABETIC DRUGS
- 1.9.1 Price Analysis
- 1.9.2 Market Analysis
- 1.10 LEADING COMPETITORS IN THE DIABETES DEVICES MARKET
- 1.11 LEADING COMPETITORS IN THE INSULIN AND ANTIDIABETIC DRUG MARKET
RESEARCH METHODOLOGY
- 2.1 RESEARCH SCOPE
- 2.2 IDATA'S 9-STEP METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
OVERVIEW OF DIABETES
- 3.1 INTRODUCTION
- 3.2 MAIN TYPES OF DIABETES
- 3.2.1 Type 1 Diabetes
- 3.2.2 Type 2 Diabetes
- 3.2.3 Gestational Diabetes
- 3.2.4 Prediabetes
- 3.3 DIABETES COMPLICATIONS
- 3.4 RISK FACTORS ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES
- 3.5 SIGNS AND SYMPTOMS
- 3.6 MONITORING
- 3.6.1 Initial Diagnosis
- 3.6.2 Blood Glucose Monitoring Systems
- 3.6.3 Urinary Glucose Monitoring
- 3.6.4 Noninvasive and Minimally Invasive Monitoring Devices
- 3.7 TREATMENT
- 3.7.1 Lifestyle Measures
- 3.7.2 Insulin
- 3.7.3 Oral Antidiabetic Drugs
- 3.7.4 Injectable Antidiabetic Drugs
- 3.8 DRUG DELIVERY
- 3.8.1 Insulin Syringes
- 3.8.2 Insulin Pens
- 3.8.3 Insulin Pumps
- 3.8.4 Inhaled Insulin
- 3.8.5 Insulin Patches
- 3.9 EMERGING TECHNOLOGIES
- 3.10 MARKET OVERVIEW
- 3.11 MARKET ANALYSIS BY SEGMENT
- 3.12 TREND ANALYSIS AND FORECAST BY SEGMENT
- 3.13 MARKET DRIVERS AND LIMITERS
- 3.13.1 Market Drivers
- 3.13.2 Market Limiters
- 3.14 COMPETITIVE ANALYSIS
DIABETES IN THE U.S.
- 4.1 DIABETES PREVALENCE
- 4.2 DIABETES INCIDENCE
- 4.3 DIABETES DEMOGRAPHICS
- 4.4 OBESITY PREVALENCE
TRADITIONAL BLOOD GLUCOSE METERS
- 5.1 INTRODUCTION
- 5.2 MARKET ANALYSIS AND FORECAST
- 5.2.1 Total Blood Glucose Monitoring Market
- 5.2.2 Total Traditional Blood Glucose Meter Market
- 5.2.3 Professional Traditional Blood Glucose Meter Market
- 5.2.4 Personal Traditional Blood Glucose Meter Market
- 5.3 MARKET DRIVERS AND LIMITERS
- 5.3.1 Market Drivers
- 5.3.2 Market Limiters
- 5.4 COMPETITIVE ANALYSIS
CONTINUOUS GLUCOSE MONITORING SYSTEMS
- 6.1 INTRODUCTION
- 6.2 MARKET ANALYSIS AND FORECAST
- 6.2.1 Total Blood Glucose Monitoring Market
- 6.2.2 Continuous Glucose Monitoring System Market
- 6.3 MARKET DRIVERS AND LIMITERS
- 6.3.1 Market Drivers
- 6.3.2 Market Limiters
- 6.4 COMPETITIVE ANALYSIS
BLOOD GLUCOSE TEST STRIPS
- 7.1 INTRODUCTION
- 7.2 MARKET ANALYSIS AND FORECAST
- 7.2.1 Total Blood Glucose Monitoring Market
- 7.2.2 Diabetic Population Using Blood Glucose Monitor Test
- 7.2.3 Total Blood Glucose Test Strip Market
- 7.2.4 Professional Blood Glucose Test Strip Market
- 7.2.5 Personal Blood Glucose Test Strip Market
- 7.3 MARKET DRIVERS AND LIMITERS
- 7.3.1 Market Drivers
- 7.3.2 Market Limiters
- 7.4 COMPETITIVE ANALYSIS
LANCETS AND LANCING DEVICES
- 8.1 INTRODUCTION
- 8.2 MARKET ANALYSIS AND FORECAST
- 8.2.1 Total Blood Glucose Monitoring Market
- 8.2.2 Total Lancet and Lancing Device Market
- 8.2.3 Professional Lancet and Lancing Device Market
- 8.2.4 Personal Lancet and Lancing Device Market
- 8.3 MARKET DRIVERS AND LIMITERS
- 8.3.1 Market Drivers
- 8.3.2 Market Limiters
- 8.4 COMPETITIVE ANALYSIS
INSULIN
- 9.1 INTRODUCTION
- 9.2 MARKET ANALYSIS AND FORECAST
- 9.2.1 Total Insulin Market
- 9.2.2 Rapid-Acting Insulin Analogs
- 9.2.3 Regular and Intermediate-Acting Human Insulin
- 9.2.4 Long-Acting Insulin Analog
- 9.2.5 Insulin Mixtures
- 9.3 MARKET DRIVERS AND LIMITERS
- 9.3.1 Market Drivers
- 9.3.2 Market Limiters
- 9.4 COMPETITIVE ANALYSIS
INSULIN SYRINGES
- 10.1 INTRODUCTION
- 10.2 MARKET ANALYSIS AND FORECAST
- 10.2.1 Total Insulin Syringe Market
- 10.2.2 Professional Insulin Syringe Market
- 10.2.3 Personal Insulin Syringe Market
- 10.3 MARKET DRIVERS AND LIMITERS
- 10.3.1 Market Drivers
- 10.3.2 Market Limiters
- 10.4 COMPETITIVE ANALYSIS
INSULIN PENS
- 11.1 INTRODUCTION
- 11.2 MARKET ANALYSIS AND FORECAST
- 11.3 MARKET DRIVERS AND LIMITERS
- 11.3.1 Market Drivers
- 11.3.2 Market Limiters
- 11.4 COMPETITIVE ANALYSIS
INSULIN PUMPS
- 12.1 INTRODUCTION
- 12.2 MARKET ANALYSIS AND FORECAST
- 12.2.1 Total Insulin Pump and Insulin Pump Infusion Set Market
- 12.2.2 Insulin Pump Market
- 12.2.3 Insulin Pump Infusion Set Market
- 12.3 MARKET DRIVERS AND LIMITERS
- 12.3.1 Market Drivers
- 12.3.2 Market Limiters
- 12.4 COMPETITIVE ANALYSIS
ORAL ANTIDIABETIC DRUGS
- 13.1 INTRODUCTION
- 13.2 MARKET ANALYSIS AND FORECAST
- 13.2.1 Total Oral Antidiabetic Drug Market
- 13.2.1.1 Unit Analysis
- 13.2.1.2 Price Analysis
- 13.2.1.3 Market Analysis
- 13.2.2 Alpha-Glucosidase Inhibitors
- 13.2.3 Biguanides
- 13.2.3.1 Total Biguanide Market
- 13.2.3.2 Brand Name Biguanide Market
- 13.2.3.3 Generic Biguanide Market
- 13.2.4 DPP-IV Inhibitors
- 13.2.5 Sulfonylureas
- 13.2.5.1 Total Sulfonylurea Market
- 13.2.5.2 Brand Name Sulfonylurea Market
- 13.2.5.3 Generic Sulfonylurea Market
- 13.2.6 Meglitinides
- 13.2.7 Thiazolidinediones
- 13.2.8 Single Pill Combinations
- 13.3 MARKET DRIVERS AND LIMITERS
- 13.3.1 Market Drivers
- 13.3.2 Market Limiters
- 13.4 COMPETITIVE ANALYSIS
INJECTABLE ANTIDIABETIC DRUGS
- 14.1 INTRODUCTION
- 14.2 MARKET ANALYSIS AND FORECAST
- 14.2.1 Total Injectable Antidiabetic Drug Market
- 14.2.1.1 Unit Analysis
- 14.2.1.2 Price Analysis
- 14.2.1.3 Market Analysis
- 14.2.2 GLP-1 Receptor Agonists
- 14.2.3 Amylinomimetics
- 14.3 MARKET DRIVERS AND LIMITERS
- 14.3.1 Market Drivers
- 14.3.2 Market Limiters
- 14.4 COMPETITIVE ANALYSIS
ABBREVIATIONS
LIST OF FIGURES
- EXECUTIVE SUMMARY
- RESEARCH METHODOLOGY
- OVERVIEW OF DIABETES
- Figure 3-1: Major Types of Diabetes and Related Pathologies
- Figure 3-2: Risk Factors Associated with Type 1 and Type 2 Diabetes
- Figure 3-3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes
- Figure 3-4: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009
- Figure 3-5: Total Diabetes Diagnosis, Treatment and Drug Delivery Market
Segment, U.S., 2006 - 2016
- Figure 3-6: Trend Analysis, Growth Rates by Market Segment, U.S. Market
for Diabetics Diagnosis, Treatment and Drug Delivery, 2006 - 2016
- Figure 3-7: Drivers and Limiters in the U.S. Market for Diabetes
Diagnosis, Treatment and Drug Delivery, 2009
- Figure 3-8: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 1)
- Figure 3-9: Leading Competitors in the Diabetes Diagnosis, Monitoring,
Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 2)
- Figure 3-10: Leading Competitors in the Devices Segment of the Total
Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009
- Figure 3-11: Leading Competitors in the Insulin and Antidiabetic Drug
Segment of the Total Market for Diabetes Diagnosis, Treatment and Drug
Delivery, U.S., 2009
- DIABETES IN THE U.S.
- Figure 4-1: Total Prevalence of Diabetes Both Diagnosed and Undiagnosed,
Adults Aged 18 - 79, U.S., 2006 - 2016
- Figure 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016
- Figure 4-3: Percentage of Population Diagnosed with Diabetes by Race and
Sex, U.S., 2006 - 2016
- Figure 4-4: Obesity Prevalence in Adults by State, Alabama to Mississippi,
U.S., 2008 (Part 1)
- Figure 4-5: Obesity Prevalence in Adults by State, Missouri to Wyoming,
U.S., 2008 (Part 2)
- TRADITIONAL BLOOD GLUCOSE METERS
- Figure 5-1: Blood Glucose Ranges Recommended by the American Diabetes
Association (ADA), U.S., 2009
- Figure 5-2: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
- Figure 5-3: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 - 2016
- Figure 5-4: Professional Traditional Blood Glucose Meter Market, U.S.,
2006 - 2016
- Figure 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006
2016
- Figure 5-6: Drivers and Limiters, Traditional Blood Glucose Meter Market,
U.S., 2009
- Figure 5-7: Leading Competitors in the Traditional Blood Glucose Meter
Market, U.S., 2009
- CONTINUOUS GLUCOSE MONITORING SYSTEMS
- Figure 6-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
- Figure 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016
- Figure 6-3: Drivers and Limiters, Continuous Glucose Monitoring System
Market, U.S., 2009
- Figure 6-4: Leading Competitors in the Continuous Glucose Monitoring
System Market, U.S., 2009
- BLOOD GLUCOSE TEST STRIPS
- Figure 7-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
- Figure 7-2: Diabetic Population Using Blood Glucose Monitor Test Strips,
U.S., 2006 - 2016
- Figure 7-3: Total Blood Glucose Test Strip Market by Segment, U.S., 2006
2016
- Figure 7-4: Professional Blood Glucose Test Strip Market by Segment, U.
2006 - 2016
- Figure 7-5: Personal Blood Glucose Test Strip Market by Segment, U.S.,
2006 2016
- Figure 7-6: Drivers and Limiters, Blood Glucose Test Strips Market, U.S.,
2009
- Figure 7-7: Leading Competitors in the Blood Glucose Test Strips Market,
U. 2009
- LANCETS AND LANCING DEVICES
- Figure 8-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016
- Figure 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 - 2016
- Figure 8-3: Professional Market for Lancets and Lancing Devices, U.S.,
2006 - 2016
- Figure 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006-
2016
- Figure 8-5: Drivers and Limiters, Lancet and Lancing Device Market, U.S.,
2009
- Figure 8-6: Leading Competitors in the Lancet and Lancing Device Market,
U.S., 2009
- INSULIN
- Figure 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009
- Figure 9-2: Brand Name Insulin, U.S., 2009
- Figure 9-3: Total Market for Insulin by Segment, U.S., 2006 - 2016
- Figure 9-4: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016
- Figure 9-5: Regular and Intermediate-Acting Human Insulin Market, U.S.,
2006 - 2016
- Figure 9-6: Long-Acting Insulin Analog Market, U.S., 2006 - 2016
- Figure 9-7: Insulin Mixture Market, U.S., 2006 - 2016
- Figure 9-8: Drivers and Limiters for the Insulin Market, U.S., 2009
- Figure 9-9: Leading Competitors in the Insulin Market, U.S., 2009
- INSULIN SYRINGES
- Figure 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 -
2016
- Figure 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016
- Figure 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016
- Figure 10-4: Drivers and Limiters for the Insulin Syringe Market, U.S.,
2009
- Figure 10-5: Leading Competitors in the Total Insulin Syringe Market,
U.S., 2009
- INSULIN PENS
- Figure 11-1: Insulin Pens Market, U.S., 2006 - 2016
- Figure 11-2: Drivers and Limiters for the Insulin Pen Market, U.S., 2009.
- Figure 11-3: Leading Competitors in the Insulin Pen Market, U.S., 2009
- INSULIN PUMPS
- Figure 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets
Segment, U.S., 2006 - 2016
- Figure 12-2: Insulin Pump Market, U.S., 2006 - 2016
- Figure 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016
- Figure 12-4: Drivers and Limiters for the Insulin Pump Market, U.S., 2009
- Figure 12-5: Leading Competitors in the Insulin Pump Market, U.S., 2009
- ORAL ANTIDIABETIC DRUGS
- Figure 13-1: Oral Antidiabetic Drug Overviews, U.S., 2009
- Figure 13-2: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 1)
- Figure 13-3: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 2)
- Figure 13-4: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 3)
- Figure 13-5: Oral Antidiabetic Drugs, U.S., 2009 (Part 1)
- Figure 13-6: Oral Antidiabetic Drugs, U.S., 2009 (Part 2)
- Figure 13-7: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 1)
- Figure 13-8: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 2)
- Figure 13-9: Oral Antidiabetic Drugs FDA Approval and Patent Expiry, U.S.,
2009 (Part 1)
- Figure 13-10: Oral Antidiabetic Drug Units, U.S., 2009
- Figure 13-11: Oral Antidiabetic Drug Price Indices, U.S., 2009
- Figure 13-12: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 -
2016
- Figure 13-13: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016
- Figure 13-14: Total Biguanide Market by Segment, U.S., 2006 - 2016
- Figure 13-15: Brand-Name Biguanide Market, U.S., 2006 - 2016
- Figure 13-16: Generic Biguanide Market, U.S., 2006 - 2016
- Figure 13-17: DPP-IV Inhibitor Market, U.S., 2006 - 2016
- Figure 13-18: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016
- Figure 13-19: Brand-Name Sulfonylurea Market, U.S., 2006 - 2016
- Figure 13-20: Generic Sulfonylurea Market, U.S., 2006 - 2016
- Figure 13-21: Meglitinide Market, U.S., 2006 - 2016
- Figure 13-22: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016
- Figure 13-23: Single Pill Combination Market, U.S., 2006 - 2016
- Figure 13-24: Drivers and Limiters for the Oral Antidiabetic Drug Market,
U.S., 2009
- Figure 13-25: Leading Competitors in the Oral Antidiabetic Drug Market,
U.S., 2009
- INJECTABLE ANTIDIABETIC DRUGS
- Figure 14-1: Injectable Antidiabetic Drug Indications, U.S., 2009
- Figure 14-2: Injectable Antidiabetic Drugs, U.S., 2009
- Figure 14-3: Injectable Antidiabetic Drugs, U.S., 2009
- Figure 14-4: Injectable Antidiabetic Drugs, FDA Approval and Patent
Expiry, U.S., 2009
- Figure 14-5: Injectable Antidiabetic Drug Units, U.S., 2009
- Figure 14-6: Injectable Antidiabetic Drug Price Indices, U.S., 2009
- Figure 14-7: Total Injectable Antidiabetic Drug Market by Segment, U.S.,
2006 - 2016
- Figure 14-8: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016
- Figure 14-9: Amylinomimetic Market, U.S., 2006 - 2016
- Figure 14-10: Drivers and Limiters for the Injectable Antidiabetic Drug
Market, U.S., 2009
- Figure 14-11: Leading Competitors in the Injectable Antidiabetic Drug
Market, U.S., 2009
- ABBREVIATIONS
LIST OF CHARTS
- EXECUTIVE SUMMARY
- Chart 1-1: Market for Diabetes Diagnosis, Treatment and Drug Delivery,
U.S., 2006 - 2016
- Chart 1-2: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment
and Drug Delivery Market, U.S., 2006 - 2016
- Chart 1-3 : Blood Glucose Test Strips as a Proportion of the Total Blood
Glucose Monitoring Market, U.S., 2009
- Chart 1-4: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 - 79, U.S., 2006 - 2016
- Chart 1-5: Average Onset, Peak and Duration of Insulin Types Used in the
U.S., 2009
- Chart 1-6: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016
- Chart 1-7: Insulin Pump Market by Segment, U.S., 2006 - 2016
- Chart 1-8: Price Index Comparison, Oral Antidiabetic Drugs, U.S., 2009
- Chart 1-9: Market Growth Analysis, Oral Antidiabetic Drugs, U.S., 2009
- Chart 1-10: Leading Competitors in the Combined Market for Diabetes
Devices, U.S., 2009
- Chart 1-11: Leading Competitors in the Combined Market for Insulin and
Antidiabetic Drugs, U.S., 2009
- RESEARCH METHODOLOGY
- OVERVIEW OF DIABETES
- Chart 3-1: Total Diabetes Diagnosis, Treatment and Drug Delivery Market,
U.S., 2006 - 2016
- Chart 3-2: Total Diabetes Diagnosis, Monitoring, Treatment and Drug
Delivery Market by Segment, U.S., 2009
- Chart 3-3: Total Diabetes Diagnosis, Monitoring, Treatment and Drug
Delivery Market by Segment, U.S., 2016
- Chart 3-4: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment
and Drug Delivery Market, U.S., 2006 - 2016
- Chart 3-5: Leading Competitors in the Total Diabetes Diagnosis,
Monitoring, Treatment and Drug Delivery Market, U.S., 2006 - 2016
- Chart 3-6: Leading Competitors in the Devices Segment of the Total Market
for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009
- Chart 3-7: Leading Competitors in the Insulin and Antidiabetic Drug
Segment the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery,
U.S., 2009
- DIABETES IN THE U.S.
- Chart 4-1: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults
Aged 18 - 79, U.S., 2006 - 2016
- Chart 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016
- Chart 4-3: Percentage of Population Diagnosed with Diabetes by Race and
Sex, U.S., 2009
- Chart 4-4: Obesity Prevalence in Adults by State, U.S., 2008
- TRADITIONAL BLOOD GLUCOSE METERS
- Chart 5-1: Traditional Blood Glucose Monitors as a Proportion of the Total
Blood Glucose Monitoring Market, U.S., 2009
- Chart 5-2: Total Traditional Blood Glucose Meter Market by Segment, U.S.,
2006 - 2016
- Chart 5-3: Professional Traditional Blood Glucose Meter Market, U.S., 2006
- 2016
- Chart 5-4: Personal Traditional Blood Glucose Meter Market Segmented by
Price Range, U.S., 2009
- Chart 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 -
2016
- Chart 5-6: Leading Competitors in the Blood Glucose Monitoring Device
Market, U.S., 2009
- CONTINUOUS GLUCOSE MONITORING SYSTEMS
- Chart 6-1: Continuous Glucose Monitoring Systems as a Proportion of the
Total Blood Glucose Monitoring Market, U.S., 2009
- Chart 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016
- Chart 6-3: Leading Competitors in the Continuous Glucose Monitoring System
Market, U.S., 2009
- BLOOD GLUCOSE TEST STRIPS
- Chart 7-1: Blood Glucose Test Strips as a Proportion of the Total Blood
Glucose Monitoring Market, U.S., 2009
- Chart 7-2: Total Blood Glucose Test Strip Market by Segment, U.S., 2006
2016
- Chart 7-3: Professional Blood Glucose Test Strip Market by Segment, U.S.,
2006 - 2016
- Chart 7-4: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006
- 2016
- Chart 7-5: Leading Competitors in the Blood Glucose Test Strips Market,
U.S., 2009
- LANCETS AND LANCING DEVICES
- Chart 8-1: Lancets and Lancing Devices as a Proportion of the Total Blood
Glucose Monitoring Market, U.S., 2009
- Chart 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,
2006 - 2016
- Chart 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006
- 2016
- Chart 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 -
2016
- Chart 8-5: Leading Competitors in the Lancet and Lancing Device Market,
U.S., 2009
- INSULIN
- Chart 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009
- Chart 9-2: Total Market for Insulin by Segment, U.S., 2006 - 2016
- Chart 9-3: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016
- Chart 9-4: Regular and Intermediate-Acting Human Insulin Market, U.S.,
2006 - 2016
- Chart 9-5: Long-Acting Insulin Analog Market, U.S., 2006 - 2016
- Chart 9-6: Insulin Mixture Market, U.S., 2006 - 2016
- Chart 9-7: Leading Competitors in the Insulin Market, U.S., 2009
- INSULIN SYRINGES
- Chart 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016
- Chart 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016
- Chart 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016
- Chart 10-4: Leading Competitors in the Total Insulin Syringe Market, U.S.,
2009
- INSULIN PENS
- Chart 11-1: Insulin Pen Market, U.S., 2006 - 2016
- Chart 11-2: Leading Competitors in the Insulin Pen Market, U.S., 2009
- INSULIN PUMPS
- Chart 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets
Segment, U.S., 2006 - 2016
- Chart 12-2: Insulin Pump Market, U.S., 2006 - 2016
- Chart 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016
- Chart 12-4: Leading Competitors in the Insulin Pump Market, U.S., 2009
- ORAL ANTIDIABETIC DRUGS
- Chart 13-1: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 -
2016
- Chart 13-2: Total Oral Antidiabetic Drug Market by Segment, U.S., 2009
- Chart 13-3: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016
- Chart 13-4: Total Biguanide Market by Segment, U.S., 2006 - 2016
- Chart 13-5: Brand Name Biguanide Market, U.S., 2006 - 2016
- Chart 13-6: Generic Biguanide Market, U.S., 2006 - 2016
- Chart 13-7: DPP-IV Inhibitor Market, U.S., 2006 - 2016
- Chart 13-8: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016
- Chart 13-9: Brand Name Sulfonylurea Market, U.S., 2006 - 2016
- Chart 13-10: Generic Sulfonylurea Market, U.S., 2006 - 2016
- Chart 13-11: Meglitinide Market, U.S., 2006 - 2016
- Chart 13-12: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016
- Chart 13-13: Single Pill Combination Market, U.S., 2006 - 2016
- Chart 13-14: Leading Competitors in the Oral Antidiabetic Drug Market,
U.S., 2009
- INJECTABLE ANTIDIABETIC DRUGS
- Chart 14-1: Total Injectable Antidiabetic Drug Market by Segment, U.S.,
2006 - 2016
- Chart 14-2: Total Injectable Antidiabetic Drug Market by Segment, U.S.,
2009
- Chart 14-3: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016
- Chart 14-4: Amylinomimetic Market, U.S., 2006 - 2016
- Chart 14-5: Leading Competitors in the Injectable Antidiabetic Drug
Market, U.S., 2009
- ABBREVIATIONS
|
 |
